Man Group PLC Vericel Corp Transaction History

Man Group PLC

$36 Billion
Q3 2024

A detailed history of Man Group PLC transactions in Vericel Corp stock. As of the latest transaction made, Man Group PLC holds 13,417 shares of VCEL stock, worth $758,060. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,417

Previous 75,032 82.12%

Holding current value

$758,060

Previous $3.44 Million 83.56%

% of portfolio

0.0%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$42.25 - $53.56 $2.6 Million - $3.3 Million	-61,615 Reduced 82.12%	13,417 $566,000
Q2 2024 Aug 14, 2024	SELL	$41.71 - $52.9 $1.13 Million - $1.44 Million	-27,197 Reduced 26.6%	75,032 $3.44 Million
Q1 2024 May 15, 2024	SELL	$32.52 - $52.33 $1.73 Million - $2.78 Million	-53,071 Reduced 34.17%	102,229 $5.32 Million
Q4 2023 Feb 14, 2024	BUY	$30.85 - $37.09 $1.32 Million - $1.59 Million	42,900 Added 38.17%	155,300 $5.53 Million
Q3 2023 Nov 14, 2023	BUY	$31.69 - $39.25 $2.65 Million - $3.28 Million	83,500 Added 288.93%	112,400 $3.77 Million
Q2 2023 Aug 14, 2023	SELL	$29.0 - $38.37 $606,100 - $801,933	-20,900 Reduced 41.97%	28,900 $1.09 Million
Q1 2023 May 15, 2023	BUY	$23.85 - $31.34 $1.19 Million - $1.56 Million	49,800 New	49,800 $1.46 Million
Q1 2021 May 17, 2021	SELL	$30.93 - $59.48 $624,786 - $1.2 Million	-20,200 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$18.53 - $31.5 $374,306 - $636,300	20,200 New	20,200 $624,000
Q1 2020 May 15, 2020	SELL	$7.25 - $19.22 $125,990 - $334,005	-17,378 Closed	0 $0
Q4 2019 Feb 18, 2020	BUY	$13.77 - $19.2 $239,295 - $333,657	17,378 New	17,378 $303,000

Others Institutions Holding VCEL

# of Institutions

276

Shares Held

48.5M

Call Options Held

91.8K

Put Options Held

23.2K

View Full List

About Vericel Corp

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.67B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

More about VCEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account